New (and not so new) antibacterial targets - From where and when will the novel drugs come?

Current Opinion in Pharmacology

Volumn 2, Issue 5, 2002, Pages 513-522

  Projan, Steven J ^a  

^a WYETH RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTINONIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; BETA LACTAMASE INHIBITOR; CERULENIN; CLAVULANIC ACID; FOSFOMYCIN; ISONIAZID; LYSOSTAPHIN; NUCLEOSIDE ANALOG; PENICILLIN G; PEPTIDE DEFORMYLASE; PEPTIDE DEFORMYLASE INHIBITOR; PIPERACILLIN PLUS TAZOBACTAM; RAMOPLANIN; RIFAMPICIN; RIFAMYCIN DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SULFAMETHOXAZOLE; SULTAMICILLIN; TEICOPLANIN; TETRACYCLINE DERIVATIVE; THIOLACTOMYCIN; TIMENTIN; TRICLOSAN; TRIMETHOPRIM; UNINDEXED DRUG; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL CELL WALL; BACTERIAL GROWTH; BACTERIAL INFECTION; BACTERIAL VIRULENCE; CRYSTAL STRUCTURE; DRUG SCREENING; DRUG TARGETING; FATTY ACID SYNTHESIS; GENE EXPRESSION REGULATION; HOST PATHOGEN INTERACTION; ION TRANSPORT; NONHUMAN; PRIORITY JOURNAL; RIBOSOME; TRANSLATION REGULATION;

EID: 0036791627     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4892(02)00197-2     Document Type: Review

References (50)

1. Sahyoun NR, Lentzner H, Hoyert D, Robinson KN: Trends in causes of death among the elderly. Aging Trends 2002, 1:1-10.
2. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM: Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001, 345:1098-1104.
3. DeCenzo M, Kuranda M, Cohen S, Babiak J, Jiang ZD, Sun DY, Hickey M, Sancheti P, Bradford PA, Youngman P et al.: Identification of compounds that inhibit late steps of peptidoglycan synthesis in bacteria. J Antibiot (Tokyo) 2002, 55:288-295.
4. Barbosa MDFS, Yang GY, Fang J, Kurilla MG, Pompliano DL: Development of a whole-cell assay for peptidoglycan biosynthesis inhibitors. Antimicrob Agents Chemother 2002, 46:943-946.
5. Henriques Normark B, Novak R, Ortqvist A, Kallenius G, Tuomanen E, Normark S: Clinical isolates of Streptococcus pneumoniae that exhibit tolerance of vancomycin. Clin Infect Dis 2001, 32:552-558.
6. Charpentier E, Tuomanen E: Mechanisms of antibiotic resistance and tolerance in Streptococcus pneumoniae. Microbes Infect 2000, 2:1855-1864.
7. Moreillon P, Markiewicz Z, Nachman S, Tomasz A: Two bactericidal targets for penicillin in pneumococci: autolysis-dependent and autolysis-independent killing mechanisms. Antimicrob Agents Chemother 1990, 34:33-39.
8. Dajcs JJ, Thibodeaux BA, Hume EBH, Zheng XD, Sloop GD, O'Callaghan RJ: Lysostaphin is effective in treating methicillin-resistant Staphylococcus aureus endophthalmitis in the rabbit. Curr Eye Res 2001, 22:451-457.
9. Climo MW, Ehlert K, Archer GL: Mechanism and suppression of lysostaphin resistance in oxacillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2001, 45:1431-1437.
10. Fischetti VA: Phage antibacterials make a comeback. Nat Biotechnol 2001, 19:734-735.
11. Nelson D, Loomis L, Fischetti VA: Prevention and elimination of upper respiratory colonization of mice by group A streptococci by using a bacteriophage lytic enzyme. Proc Natl Acad Sci USA 2001, 98:4107-4112.
12. Heath RJ, White SW, Rock CO: Lipid biosynthesis as a target for antibacterial agents. Prog Lipid Res 2001, 40:467-497.
13. Kay BK, Hamilton PT: Identification of enzyme inhibitors from phage-displayed combinatorial peptide libraries. Comb Chem High Throughput Screen 2001, 4:535-543.
14. Scheffers DJ, Driessen AJM: The polymerization mechanism of the bacterial cell division protein FtsZ. FEBS Lett 2001, 506:6-10.
15. Pichoff S, Lutkenhaus J: Escherichia coli division inhibitor MinCD blocks septation by preventing Z-ring formation. J Bacteriol 2001, 183:6630-6635.
16. Haney SA, Glasfeld E, Hale C, Keeney D, He Z, de Boer P: Genetic analysis of the Escherichia coli FtsZ.ZipA interaction in the yeast two-hybrid system. Characterization of FtsZ residues essential for the interactions with ZipA and with FtsA. J Biol Chem 2001, 276:11980-11987.
17. Antin PB, Forry-Schaudies S, Friedman TM, Tapscott SJ, Holtzer H: Taxol induces postmitotic myoblasts to assemble interdigitating microtubule-myosin arrays that exclude actin filaments. J Cell Biol 1981, 90:300-308.
18. Ramakrishnan V: Ribosome structure and the mechanism of translation. Cell 2002, 108:557-572.
19. Vicens Q, Westhof E: Crystal structure of paromomycin docked into the eubacterial ribosomal decoding a site. Structure 2001, 9:647-658.
20. Schmeing TM, Seila AC, Hansen JL, Freeborn B, Soukup JK, Scaringe SA, Strobel SA, Moore PB, Steitz TA: A pre-translocational intermediate in protein synthesis observed in crystals of enzymatically active 50S subunits. Nat Struct Biol 2002, 9:225-230.
21. Brodersen DE, Clemons WM, Carter AP, Morgan-Warren RJ, Wimberly BT, Ramakrishnan V: The structural basis for the action of the antibiotics tetracycline, pactamycin, and hygromycin B on the 30S ribosomal subunit. Cell 2000, 103:1143-1154.
22. Yuan ZY, Trias J, White RJ: Deformylase as a novel antibacterial target. Drug Discov Today 2001, 6:954-961.
23. Chen DZ, Patel DV, Hackbarth CJ, Wang W, Dreyer G, Young DC, Margolis PS, Wu C, Ni ZJ, Trias J et al.: Actinonin, a naturally occurring antibacterial agent, is a potent deformylase inhibitor. Biochemistry 2000, 39:1256-1262.
24. Wise R, Andrews JM, Ashby J: In vitro activities of peptide deformylase inhibitors against Gram-positive pathogens. Antimicrob Agents Chemother 2002, 46:1117-1118.
25. Margolis PS, Hackbarth CJ, Young DC, Wang W, Chen D, Yuan ZY, White R, Trias J: Peptide deformylase in Staphylococcus aureus: resistance to inhibition is mediated by mutations in the formyltransferase gene. Antimicrob Agents Chemother 2000, 44:1825-1831.
26. Busby S, Ebright RH: Promoter structure, promoter recognition, and transcription activation in prokaryotes. Cell 1994, 79:743-746.
27. Delgado MA, Rintoul MR, Farias RN, Salomon RA: Escherichia coli RNA polymerase is the target of the cyclopeptide antibiotic microcin J25. J Bacteriol 2001, 183:4543-4550.
28. Bruck I, O'Donnell M: The DNA replication machine of a Gram-positive organism. J Biol Chem 2000, 275:28971-28983.
29. Song MS, Pham PT, Olson M, Carter JR, Franden MA, Schaaper RM, McHenry CS: The delta and delta subunits of the DNA polymerase III holoenzyme are essential for initiation complex formation and processive elongation. J Biol Chem 2001, 276:35165-35175.
30. Zhang LT, Schwartz G, O'Donnell M, Harrison RK: Development of a novel helicase assay using electrochemiluminescence. Anal Biochem 2001, 293:31-37.
31. Goossens H: MYSTIC program: summary of European data from 1997 to 2000. Diagn Microbiol Infect Dis 2001, 41:183-189.
32. Winokur PL, Vonstein DL, Hoffman LJ, Uhlenhopp EK, Doern GV: Evidence for transfer of CMY-2 AmpC beta-lactamase plasmids between Escherichia coli and Salmonella isolates from food animals and humans. Antimicrob Agents Chemother 2001, 45:2716-2722.
33. Randegger CC, Hachler H: Amino acid substitutions causing inhibitor resistance in TEM beta-lactamases compromise the extended-spectrum phenotype in SHV extended-spectrum beta-lactamases. J Antimicrob Chemother 2001, 47: 547-554.
34. Miller LA, Ratnam K, Payne DJ: β-Lactamase-inhibitor combinations in the 21st century: current agents and new developments. Curr Opin Pharmacol 2001, 1:451-458.
35. Kumar S, Pearson AL, Pratt RF: Design, synthesis, and evaluation of alpha-ketoheterocycles as class C beta-lactamase inhibitors. Bioorg Med Chem 2001, 9:2035-2044.
36. Mollard C, Moali C, Papamicael C, Damblon C, Vessilier S, Amicosante G, Schofield CJ, Galleni M, Frere JM, Roberts GCK: Thiomandelic acid, a broad spectrum inhibitor of zinc beta-lactamases - kinetic and spectroscopic studies. J Biol Chem 2001, 276:45015-45023.
37. Projan SJ: Preclinical pharmacology of GAR-936, a novel glycylcycline antibacterial agent. Pharmacotherapy 2000, 20:219S-223S.
38. Nikaido H: Preventing drug access to targets: cell surface permeability barriers and active efflux in bacteria. Semin Cell Dev Biol 2001, 12:215-223.
39. Lomovskaya O, Watkins WJ: Efflux pumps: their role in antibacterial drug discovery. Curr Med Chem 2001, 8:1699-1711.
40. Renau TE, Leger R, Yen R, She MW, Flamme EM, Sangalang J, Gannon CL, Chamberland S, Lomovskaya O, Lee VJ: Peptidomimetics of efflux pump inhibitors potentiate the activity of levofloxacin in Pseudomonas aeruginosa. Bioorg Med Chem Lett 2002, 12:763-766.
41. Alksne LE, Projan SJ: Bacterial virulence as a target for antimicrobial chemotherapy. Curr Opin Biotechnol 2000, 11:625-636.
42. Lyon GJ, Wright JS, Christopoulos A, Novick RP, Muir TW: Reversible and specific extracellular antagonism of receptor-histidine kinase signaling. J Biol Chem 2002, 277:6247-6253
43. Fuqua C, Parsek MR, Greenberg EP: Regulation of gene expression by cell-to-cell communication: acyl-homoserine lactone quorum sensing. Annu Rev Genet 2001, 35:439-468.
44. Gov Y, Bitler A, Dell'Acqua G, Torres JV, Balaban N: RNAIII inhibiting peptide (RIP), a global inhibitor of Staphylococcus aureus pathogenesis: structure and function analysis. Peptides 2001, 22:1609-1620.
45. Chen X, Schauder S, Potier N, Van Dorsselaer A, Pelczer I, Bassler BL, Hughson FM: Structural identification of a bacterial quorum-sensing signal containing boron. Nature 2002, 415:545-549.
46. Miller MB, Bassler BL: Quorum sensing in bacteria. Annu Rev Microbiol 2001, 55:165-199.
47. Low DA, Weyand NJ, Mahan MJ: Roles of DNA adenine methylation in regulating bacterial gene expression and virulence. Infect Immun 2001, 69:7197-7204.
48. Alekshun MN, Levy SB, Mealy TR, Seaton BA, Head JF: The crystal structure of MarR, a regulator of multiple antibiotic resistance, at 2.3 Å resolution. Nat Struct Biol 2001, 8:710-714.
49. Liu Y, Manna A, Li R, Martin WE, Murphy RC, Cheung AL, Zhang G: Crystal structure of the SarR protein from Staphylococcus aureus. Proc Natl Acad Sci USA 2001, 98:6877-6882.
50. Hale CA, de Boer PA: Recruitment of ZipA to the septal ring of Escherichia coli is dependent on FtsZ and independent of FtsA. J Bacteriol 1999, 181:167-176.